Results 141 to 150 of about 21,002 (186)

Rapid and sensitive acute leukemia classification and diagnosis platform using deep learning-assisted SERS detection. [PDF]

Cell Rep Med
Zhang D, Cheng Z, Song Y, Li H, Shi L, Wang N, Peng Y, Chen R, Sun N, Han M, Hu F, Zong C, Zhang R, Chen S, Zhu C, Zhang X, Li X, Ma X, Shi C, Zhang X, Liu R, Ren Z, Wang L, Zeng Q, Zeng T, Chen X.   +25 more
europepmc   +1 more source

Philadelphia chromosome-positive de novo myelodysplastic syndrome with the p230 BCR::ABL1 fusion gene: a case report. [PDF]

Int J Hematol
Kawai H, Fukushima H, Nannya Y, Onizuka M, Ogawa Y, Kawada H.   +5 more
europepmc   +1 more source

A case report and a literature review of Myeloid/Lymphoid Neoplasm with Eosinophilia and PCM1::JAK2 rearrangement representing as B-cell acute lymphoblastic leukemia B-ALL. [PDF]

Ann Hematol
Čemažar L, Šlajpah K, Gredelj Šimec N, Podgornik H.   +3 more
europepmc   +1 more source

BCR-ABL tyrosine kinase inhibitors associated acute kidney injury: a pharmacovigilance study based on the FAERS database with a case report. [PDF]

BMC Nephrol
Shi Y, Deng L, Zhu J, Huang Y, Zeng M, Mao H, Huang Z, Wu B.   +7 more
europepmc   +1 more source

Biological Features of KLC2 Mutations in Chronic Myeloid Leukemia and Their Contribution to Inducing Drug Resistance. [PDF]

Oncol Res
Bera R, Ochi Y, Huang YJ, Kuo MC, Yoshida K, Ogawa S, Shih LY.   +6 more
europepmc   +1 more source

Study of the association between HDAC8, SIRT1, and P53 gene expression with drug resistance in chronic myeloid leukemia patients. [PDF]

BMC Cancer
Mansouri R, Heydarpour F, Yari K, Naseroleslami M, Payandeh M.   +4 more
europepmc   +1 more source

FDA-approved kinase inhibitors in PROTAC design, development and synthesis. [PDF]

J Enzyme Inhib Med Chem
Kossakowski K, Cherniienko A, Zaprutko L, Pawełczyk A.   +3 more
europepmc   +1 more source

Bibliometric analysis and recent trends on tyrosine kinase inhibitors in leukemia. [PDF]

Discov Oncol
Cheng J, Fang Y, Dong J, Zhang X, Yuan Y, Dang X.   +5 more
europepmc   +1 more source

Case Report: Management of a <i>BCR-ABL1</i>-positive high-risk rhabdomyosarcoma patient using tyrosine kinase inhibitors. [PDF]

Front Med (Lausanne)
Li F, Jiang D, Liu Y, Yin M, Zhong Y, Xu M, Zhang A, Han Y.   +7 more
europepmc   +1 more source

Imatinib and blinatumomab successfully rescued a pediatric B-ALL patient with TERF2::PDGFRB fusion resistant to dasatinib and chemotherapy. [PDF]

Ann Hematol
Ye F, Wang L, Qian Y, Deng W, Yu Y, Yang L.   +5 more
europepmc   +1 more source